Castle Biosciences Announces Updates to its Board of Directors
The Company further announced that Mara G. Aspinall will not stand for re-election to its board, and her current term will expire at the 2024 Annual Meeting.
- The Company further announced that Mara G. Aspinall will not stand for re-election to its board, and her current term will expire at the 2024 Annual Meeting.
- “Mara has been a great partner and contributor,” said Derek Maetzold, director, president and chief executive officer of Castle Biosciences.
- “Rod’s broad range of leadership experience in the diagnostic industry will be a significant benefit to our board.
- With Cotton’s addition, the Company’s board will be comprised of nine directors, five of whom have been appointed in the past four years.